Tina Albertson
Geen lopende functies
Vermogen: 9 029 $ op 31-03-2024
Profiel
Tina Albertson worked as the Medical Director at Seagen Inc. from 2010 to 2015.
She then served as the Vice President-Global Drug Development at Juno Therapeutics, Inc. from 2015 to 2020.
Currently, she is the Chief Medical Officer & Head-Development at Lyell Immunopharma, Inc. since 2020.
Dr. Albertson holds a doctorate degree from Stanford University, the University of Washington, and an undergraduate degree from the University of Oregon.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0.00% | 24-02-2023 | 4 049 ( 0.00% ) | 9 029 $ | 31-03-2024 |
Eerdere bekende functies van Tina Albertson
| Bedrijven | Functie | Einde |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01-11-2023 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01-04-2020 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 01-01-2015 |
Opleiding van Tina Albertson
| Stanford University | Doctorate Degree |
| University of Washington | Doctorate Degree |
| University of Oregon | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
